Do you want to read an article? Please log in or register.
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
COPD
COMMENTED
Related content
Further Publications
Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials
Respir Med
Suter P, Greig R, Chan R, Lipworth B
doi: 10.1016/j.rmed.2025.108343
RECOMMENDED
AsthmaCOPD
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Ramakrishnan S, Russell REK, Mahmood HR, Krassowska K, Melhorn J, Mwasuku C, Pavord ID, Bermejo-Sanchez L, Howell I, Mahdi M, Peterson S, Bengtsson T, Bafadhel M
doi: 10.1016/S2213-2600(24)00299-6
RECOMMENDED
Asthma
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Allergy Asthma Immunol Res
Chen R, Dai Y, Yang D, Liu C, Han W, Gu W, Cao J, Zhou Q, Howarth P, Weng S, Xiong C, Huang J, Liang P, Zhong N, 201536 Study Group
doi: 10.4168/aair.2025.17.4.473
Asthma
Real-World Respiratory Effectiveness of mepolizumab in Severe Eosinophilic Asthma and Eosinophilic Granulomatosis with Polyangiitis
Respir Med
Zhu W, Chen K, Xiang Y, Shi J, Liang Y, Tong Y, Wang S, Zeng H, Zhang L, Ning X, Ye L, Jin M
doi: 10.1016/j.rmed.2025.108223
Asthma
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry
Respir Med
Harvey ES, Hamada Y, Hiles SA, Langton D, Thomas D, McDonald VM, Bardin P, Peters M, Reynolds PN, Upham JW, Blakey J, Bowler S, Chien J, Chung LP, Farah CS, Gillman A, Harrington J, Hew M, Jenkins C, Katelaris CH, Katsoulotos GP, Kritikos V, Lee J, Radhakrishna N, Sivakumaran P, Wark PAB, Gibson PG, Australian Mepolizumab Registry Investigators
doi: 10.1016/j.rmed.2025.108340
RECOMMENDED
Asthma
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Rimkunas A, Januskevicius A, Vasyle E, Palacionyte J, Kalinauskaite-Zukauske V, Miliauskas S, Malakauskas K
doi: 10.2147/JAA.S509001
COPD
Glucocorticoid Treatment in Severe COPD Exacerbations: Biological Rationale, Clinical Effects, and Practical Advice
Semin Respir Crit Care Med
Sartori F, Sartori G, Di Chiara C, Fantin A, Crisafulli E
doi: 10.1055/a-2693-0577
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
COPDFurther Publications
Airway Mucus Plugs on Chest Computed Tomography Are Associated with Exacerbations in COPD
Am J Respir Crit Care Med
Wan E, Yen AA, Elalami R, Grumley S, Nath HP, Wang W, Brouha S, Manapragada PP, Abozeed M, Aziz MU, Zahid M, Ahmed AN, Terry NL, Nardelli P, Ross JC, Kim V, Sonavane S, Kligerman SJ, Vestbo J, Agusti A, Kim K, San José Estépar R, Silverman EK, Cho MH, Diaz AA
doi: 10.1164/rccm.202403-0632OC